NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...

Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his ...

the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week. The stock has dropped by over 49% in the ...

Novo Nordisk CEO Lars Fruergaard Jorgensen steps down amidst concerns over losing their competitive edge in the obesity drug market. Analysts react, citing the need for a CEO familiar with the U.S.

Discover the latest executive changes across major companies like UnitedHealth, Intuitive, Novo Nordisk, and more.

Novo Nordisk, a major player in the pharmaceutical industry, revealed on Friday that its CEO, Lars Fruergaard Jorgensen, is set to resign. The decision comes as Novo Nordisk grapples with recent ...

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...